Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
The risks and benefits of bedaquiline (BDQ) for treatment of drug-resistant tuberculosis (DR-TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Pulmonary Medicine |
| Online Access: | http://dx.doi.org/10.1155/2024/5542658 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850088084998193152 |
|---|---|
| author | Muhammad Candragupta Jihwaprani Yipeng Sun Wahyu Choirur Rizky Idris Sula Nazmus Saquib |
| author_facet | Muhammad Candragupta Jihwaprani Yipeng Sun Wahyu Choirur Rizky Idris Sula Nazmus Saquib |
| author_sort | Muhammad Candragupta Jihwaprani |
| collection | DOAJ |
| description | The risks and benefits of bedaquiline (BDQ) for treatment of drug-resistant tuberculosis (DR-TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceDirect, and SinoMed) were searched. RCTs among DR-TB patients that had a control arm were eligible. The safety endpoints were all-cause mortality and serious adverse effects (SAEs). Efficacy outcomes were sputum culture conversion rate at 8–12 weeks and 24–26 weeks, treatment success, and time to culture conversion. A total of 476 records were screened; 18 met the eligibility criteria. The pooled analysis included 2520 participants (55.8% received BDQ-containing regimens, n=1408). Pooled safety outcomes showed no significant reduction in all-cause mortality (relative risk [RR] 95%confidence interval CI=0.94 [0.41–2.20]) or SAEs (RR 95%CI=0.91 [0.67–1.23]) in the BDQ-regimen group. Pooled efficacy outcomes showed significantly superior culture conversion rates at 8–12 weeks (RR 95%CI=1.35 [1.10–1.65]) and 24–26 weeks (RR 95%CI=1.25 [1.15–1.36]), more treatment success (RR 95%CI=1.30 [1.17–1.44]), and a 17-day reduction in the time to culture conversion (standardized mean difference [SMD] 95%CI=−17.46 [−34.82 to −0.11]) in the BDQ-regimen group (reference: non-BDQ regimen). Overall, BDQ regimens showed significant treatment effect against DR-TB but did not reduce mortality or SAEs. |
| format | Article |
| id | doaj-art-43bddaee3e79463ca6ca37aef4eecb31 |
| institution | DOAJ |
| issn | 2090-1844 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Medicine |
| spelling | doaj-art-43bddaee3e79463ca6ca37aef4eecb312025-08-20T02:43:06ZengWileyPulmonary Medicine2090-18442024-01-01202410.1155/2024/5542658Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsMuhammad Candragupta Jihwaprani0Yipeng Sun1Wahyu Choirur Rizky2Idris Sula3Nazmus Saquib4College of MedicineCollege of MedicineDepartment of Anesthesiology and Intensive Care UnitCollege of MedicineCollege of MedicineThe risks and benefits of bedaquiline (BDQ) for treatment of drug-resistant tuberculosis (DR-TB) have not been firmly established. We aimed to assess the safety and efficacy of BDQ-containing regimens for the treatment of DR-TB as evidenced in available randomized controlled trials (RCTs). In this systematic review and meta-analysis, five databases (i.e., ClinicalTrials.gov, Cochrane CENTRAL, PubMed, ScienceDirect, and SinoMed) were searched. RCTs among DR-TB patients that had a control arm were eligible. The safety endpoints were all-cause mortality and serious adverse effects (SAEs). Efficacy outcomes were sputum culture conversion rate at 8–12 weeks and 24–26 weeks, treatment success, and time to culture conversion. A total of 476 records were screened; 18 met the eligibility criteria. The pooled analysis included 2520 participants (55.8% received BDQ-containing regimens, n=1408). Pooled safety outcomes showed no significant reduction in all-cause mortality (relative risk [RR] 95%confidence interval CI=0.94 [0.41–2.20]) or SAEs (RR 95%CI=0.91 [0.67–1.23]) in the BDQ-regimen group. Pooled efficacy outcomes showed significantly superior culture conversion rates at 8–12 weeks (RR 95%CI=1.35 [1.10–1.65]) and 24–26 weeks (RR 95%CI=1.25 [1.15–1.36]), more treatment success (RR 95%CI=1.30 [1.17–1.44]), and a 17-day reduction in the time to culture conversion (standardized mean difference [SMD] 95%CI=−17.46 [−34.82 to −0.11]) in the BDQ-regimen group (reference: non-BDQ regimen). Overall, BDQ regimens showed significant treatment effect against DR-TB but did not reduce mortality or SAEs.http://dx.doi.org/10.1155/2024/5542658 |
| spellingShingle | Muhammad Candragupta Jihwaprani Yipeng Sun Wahyu Choirur Rizky Idris Sula Nazmus Saquib Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials Pulmonary Medicine |
| title | Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_full | Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_fullStr | Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_full_unstemmed | Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_short | Establishing the Safety and Efficacy of Bedaquiline-Containing Regimen for the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials |
| title_sort | establishing the safety and efficacy of bedaquiline containing regimen for the treatment of drug resistant tuberculosis a systematic review and meta analysis of randomized clinical trials |
| url | http://dx.doi.org/10.1155/2024/5542658 |
| work_keys_str_mv | AT muhammadcandraguptajihwaprani establishingthesafetyandefficacyofbedaquilinecontainingregimenforthetreatmentofdrugresistanttuberculosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT yipengsun establishingthesafetyandefficacyofbedaquilinecontainingregimenforthetreatmentofdrugresistanttuberculosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT wahyuchoirurrizky establishingthesafetyandefficacyofbedaquilinecontainingregimenforthetreatmentofdrugresistanttuberculosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT idrissula establishingthesafetyandefficacyofbedaquilinecontainingregimenforthetreatmentofdrugresistanttuberculosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials AT nazmussaquib establishingthesafetyandefficacyofbedaquilinecontainingregimenforthetreatmentofdrugresistanttuberculosisasystematicreviewandmetaanalysisofrandomizedclinicaltrials |